HK1255212A1 - 用於治療膀胱癌的製劑 - Google Patents

用於治療膀胱癌的製劑

Info

Publication number
HK1255212A1
HK1255212A1 HK18114340.8A HK18114340A HK1255212A1 HK 1255212 A1 HK1255212 A1 HK 1255212A1 HK 18114340 A HK18114340 A HK 18114340A HK 1255212 A1 HK1255212 A1 HK 1255212A1
Authority
HK
Hong Kong
Prior art keywords
formulations
bladder cancer
treating bladder
treating
cancer
Prior art date
Application number
HK18114340.8A
Other languages
English (en)
Inventor
G‧V‧貝塔格里
N‧溫卡德森
M‧G‧厄夫來因
Original Assignee
健康科學西部大學
泰索克斯制藥有限責任公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 健康科學西部大學, 泰索克斯制藥有限責任公司 filed Critical 健康科學西部大學
Publication of HK1255212A1 publication Critical patent/HK1255212A1/zh

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Liposomes
    • A61K9/1277Processes for preparing; Proliposomes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/243Platinum; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0034Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Liposomes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
HK18114340.8A 2016-01-07 2018-11-09 用於治療膀胱癌的製劑 HK1255212A1 (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662275941P 2016-01-07 2016-01-07
US201662275936P 2016-01-07 2016-01-07
US201662421137P 2016-11-11 2016-11-11
PCT/US2017/012720 WO2017120586A1 (en) 2016-01-07 2017-01-09 Formulations for treating bladder cancer

Publications (1)

Publication Number Publication Date
HK1255212A1 true HK1255212A1 (zh) 2019-08-09

Family

ID=59274569

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18114340.8A HK1255212A1 (zh) 2016-01-07 2018-11-09 用於治療膀胱癌的製劑

Country Status (23)

Country Link
US (2) US11229602B2 (zh)
EP (1) EP3400072B1 (zh)
JP (3) JP6697541B2 (zh)
KR (1) KR20180103039A (zh)
CN (2) CN113181118A (zh)
AU (1) AU2017205337B2 (zh)
BR (1) BR112018013896A2 (zh)
CA (1) CA3009809A1 (zh)
CL (1) CL2018001838A1 (zh)
CO (1) CO2018007674A2 (zh)
CR (1) CR20180388A (zh)
DK (1) DK3400072T3 (zh)
EA (1) EA038653B1 (zh)
ES (1) ES2863659T3 (zh)
HK (1) HK1255212A1 (zh)
IL (1) IL260346B2 (zh)
MX (2) MX2018008267A (zh)
MY (1) MY198105A (zh)
PE (1) PE20181445A1 (zh)
PH (1) PH12018501451A1 (zh)
SG (1) SG11201805594PA (zh)
WO (1) WO2017120586A1 (zh)
ZA (1) ZA201804968B (zh)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018047074A1 (en) * 2016-09-07 2018-03-15 Cadila Healthcare Limited Sterile injectable compositions comprising drug micelles
NZ753214A (en) 2016-11-11 2022-02-25 Univ Western Health Sciences Methods of treating upper tract urothelial carcinomas
WO2018169960A1 (en) * 2017-03-17 2018-09-20 The Johns Hopkins University Nanoparticle formulations for enhanced drug delivery to the bladder
LU101155B1 (en) * 2017-07-19 2019-04-25 Tesorx Pharma Llc Liposomal Paclitaxel Formulation for Treating Bladder Cancer
EP3796965A4 (en) * 2018-05-04 2022-01-26 Lipac Oncology LLC BALLOON CATHETER
MX2021005110A (es) * 2018-11-02 2021-08-24 Tesorx Pharma Llc Quimioterapia intraperitoneal mejorada con liposomas.
GB201900389D0 (en) 2019-01-11 2019-02-27 Queens Univ Of Belfast Solvent and water-free lipid-based nanoparticles and their methods of manufacture
CN113189315B (zh) * 2021-04-13 2024-01-23 山东省医疗器械产品质量检验中心 评价抗菌导尿管抗菌活性的体外动态模型及其使用方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1330938C (en) 1985-10-18 1994-07-26 Abdul R. Khokhar Hydrophobic cis-platinum complexes efficiently incorporated into liposomes
US5415869A (en) * 1993-11-12 1995-05-16 The Research Foundation Of State University Of New York Taxol formulation
US5902604A (en) 1995-06-06 1999-05-11 Board Of Regents, The University Of Texas System Submicron liposome suspensions obtained from preliposome lyophilizates
ATE341310T1 (de) * 2000-02-04 2006-10-15 Lipoxen Technologies Ltd Dehydratisierungs-/rehydratisierungsverfahren zur herstellung von liposome
US8658202B2 (en) * 2001-04-25 2014-02-25 Western University Of Health Sciences Coated drug delivery formulations
DE60237162D1 (de) 2001-10-03 2010-09-09 Celator Pharmaceuticals Inc Liposomenladung mit metallionen
BRPI0407096A (pt) 2003-02-03 2006-01-24 Neopharm Inc Taxano encapsulado em lipossomo estável, estéril e filtrável e outros fármacos antineoplásicos
WO2005039534A1 (en) * 2003-10-01 2005-05-06 Children's Hospital & Research Center At Oakland Lipophilic drug delivery vehicle and methods of use thereof
WO2005072776A2 (en) 2004-01-30 2005-08-11 Instytut Farmaceutyczny Liposomal formulations of the antineoplastic agents
US20060024360A1 (en) * 2004-07-28 2006-02-02 Sd Pharmaceuticals, Inc. Stable injectable composition of alpha tocopheryl succinate, analogues and salts thereof
NZ572601A (en) 2006-03-29 2012-03-30 Univ Wayne State Liposomal nanoparticles and other formulations of fenretinide for use in therapy and drug delivery
PT2076244T (pt) * 2006-10-10 2017-03-09 Jina Pharmaceuticals Inc Sistemas aquosos para a preparação de compostos farmacêuticos à base de lípidos; composições, métodos e utilizações dos mesmos
CN101322689B (zh) * 2007-06-11 2012-10-24 江苏先声药物研究有限公司 一种多西他赛长循环脂质体及其冻干粉针的制备方法
WO2010009186A1 (en) * 2008-07-15 2010-01-21 The Board Of Trustees Of The University Of Illinois Liposome formulation having hydrophilic and hydrophobic pharmaceutical compounds co-encapsulated therein
US8956600B2 (en) * 2009-08-10 2015-02-17 Taiwan Liposome Co. Ltd. Ophthalmic drug delivery system containing phospholipid and cholesterol
WO2012094020A1 (en) * 2010-01-07 2012-07-12 Innopharma, Inc. Methods and compositions for delivery of taxanes in stable oil-in-water emulsions
SG11201407349UA (en) * 2012-05-09 2014-12-30 Univ Western Health Sciences Proliposomal testosterone formulations
CN103570766B (zh) 2012-08-09 2016-04-13 浙江海昶生物医药技术有限公司 一种新型铂类脂质体制剂及其制备方法
CN103768018A (zh) 2012-10-17 2014-05-07 南京绿叶思科药业有限公司 一种卡巴他赛脂质体注射剂及其制备方法
WO2014160337A1 (en) 2013-03-13 2014-10-02 Mallinckrodt Llc Liposomal cisplatin compositions for cancer therapy
BR112015022819A8 (pt) * 2013-03-13 2019-11-26 Mallinckrodt Llc método para a preparação de um taxano lipossomal, composição compreendendo um lipossoma e taxano lipossomal
NZ753214A (en) 2016-11-11 2022-02-25 Univ Western Health Sciences Methods of treating upper tract urothelial carcinomas

Also Published As

Publication number Publication date
DK3400072T3 (da) 2021-03-22
JP2020002181A (ja) 2020-01-09
IL260346B2 (en) 2023-08-01
JP2018528933A (ja) 2018-10-04
EP3400072A1 (en) 2018-11-14
CN108136217A (zh) 2018-06-08
IL260346A (en) 2018-08-30
ZA201804968B (en) 2022-10-26
EA201891575A1 (ru) 2019-01-31
MX2018008267A (es) 2018-09-28
AU2017205337B2 (en) 2022-09-08
IL260346B1 (en) 2023-04-01
ES2863659T3 (es) 2021-10-11
US11229602B2 (en) 2022-01-25
KR20180103039A (ko) 2018-09-18
MY198105A (en) 2023-08-02
EA038653B1 (ru) 2021-09-29
CL2018001838A1 (es) 2018-08-17
CN113181118A (zh) 2021-07-30
CN108136217B (zh) 2021-04-30
JP2022168210A (ja) 2022-11-04
US20190015334A1 (en) 2019-01-17
WO2017120586A1 (en) 2017-07-13
CR20180388A (es) 2018-09-11
CO2018007674A2 (es) 2018-08-10
AU2017205337A1 (en) 2018-07-19
JP6697541B2 (ja) 2020-05-20
BR112018013896A2 (pt) 2018-12-18
EP3400072B1 (en) 2020-12-30
SG11201805594PA (en) 2018-07-30
EP3400072A4 (en) 2020-01-08
US20210267896A1 (en) 2021-09-02
MX2020013858A (es) 2021-03-25
CA3009809A1 (en) 2017-07-13
PE20181445A1 (es) 2018-09-12
PH12018501451A1 (en) 2019-03-11

Similar Documents

Publication Publication Date Title
HK1251407A1 (zh) 治療癌症的方法
IL290149A (en) Combined treatment for cancer
IL254705B (en) Combined treatment for cancer
IL255060A0 (en) Combined treatment for cancer
HK1255212A1 (zh) 用於治療膀胱癌的製劑
IL259996A (en) Combinations for cancer treatment
IL263802A (en) Combinations of cancer treatments
HK1258319A1 (zh) 癌症療法
HK1254258A1 (zh) 使用阿吡莫德治療癌症的方法
HK1250944A1 (zh) 用於治療癌症的方法
IL272027B (en) Endothelial prodrugs for use in cancer treatment.
ZA201900052B (en) Pharmaceutical combinations for treating cancer
HK1250942A1 (zh) 用於治療癌症的方法
EP3546020C0 (en) CANCER TREATMENT DEVICE
HK1250943A1 (zh) 用於治療癌症的方法
FI3390448T3 (fi) Intravesikaalinen hoito virtsarakon syöpää varten
HK1251794A1 (zh) 癌症治療
HK1254687A1 (zh) 用於癌症的聯合療法
EP3270898A4 (en) Methods for the treatment of bladder cancer
GB201522433D0 (en) Cancer treatment
HRP20210383T8 (hr) Kombinirana terapija za rak
GB201601248D0 (en) Cancer therapy